Home > Search Results

INTRODUCTION

Thromboembolic diseases represent a major public health burden and are associated with significant morbidity and mortality. For more than 50 years, vitamin K antagonists (VKAs) have been the mainstay of treatment and prophylaxis of thromboembolism. There are many indications for VKAs, including primary prevention of systemic embolism in nonvalvular atrial fibrillation (AF) and mechanical prosthetic heart valves. Other indications include secondary prophylaxis following venous thromboembolism (VTE) and preventing stroke in patients with a mural thrombus following myocardial infarction.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...